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Antiepileptic drugs show clinically significant interactions among themselves as well as 
with other medications, because of a specific pharmacokinetic profile and relatively small 
therapeutic spectrum. The most significant clinical interactions of AE occur during their 
metabolism and distribution. In the combined antiepileptic therapy, it is very important to 
know the order of application of AE because of their influence on liver enzymes and the 
affinity to attach to plasma proteins. The AE with shorter half-time elimination have a 
greater potential for interaction which is why therapy monitoring is recommended. 
Populational pharmacokinetic analysis can provide significant information concerning 
interactions of AE with other medications. Vulnerable, pediatric population is under a 
special risk of developing interactions alongside patients with liver and kidney function 
damage. Acta Medica Medianae 2007;46(4):55-60. 
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Introduction 
 
Antiepileptic drugs show clinically significant 
interactions both with each other and with other 
medications, because of the specific pharma-
cokinetic profile and relatively narrow therapeutic 
range (1,2). 
Interactions of antiepileptic drugs (AE) 
need special attention since the treatment of 
epilepsy is long lasting and frequently life-long 
(2). Even though monotherapy is applied, it is 
often necessary to combine antiepileptic drugs 
for the reason of controlling the disease itself, AE 
characteristics and patient specific features. 
Sometimes it is indicated that epileptic patients 
take other medications because of the accompa-
nying diseases and states. 
Unpredicted changes of the patient's clinical 
condition with the controlled dosage are mainly 
caused by the occurence of interactions. Clinically 
significant interactions of AE suggest change in 
the dosage procedure in order to gain and/or 
reduce toxic effects of medications that often 
require therapeutic monitoring. Pharmacokinetic 
interactions of AE are mainly quantitive and 
easily predictible. They occur in locations of 
pharmacokinetic processes and are always 
followed by changes in the plasma concentration 
of medications. Compared to pharmacodynamic 
interactions, they are more studied and more 
easily identified and quantified (2,3). 
 
Pharmacokinetic processes significant 
for interaction occurence 
 
Absorption 
Absorption includes releasing a medication 
from its therapeutic form, its dissolving and 
enterance into system circulation (3). Medications 
that influence gastro kinetics also change 
antiepileptic kinetics. For example, metoclopra-
mide and cisapride accelerate, while propantelin 
slows down a gastric discharge, change the time 
needed for release and dissolve medicine from its 
therapeutic form (4,5). Laxatives shorten transitory 
time of antiepileptics through the digestive tract, 
reduce absorption and concentration of the 
medication in the plasma. Cytostatics damage 
cells of the intestines, change their flora and 
reduce absorption of AE (5). The influence of 
quantity and consistence of gastrointestinal fluid, 
presence of food, or patient's general condition 
should not be neglected. Primarily, the presence 
of the solid food increases gastric circulation and 
slows down intestinal mobility while the liquid 
food shows the opposite effect (6). The process 
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Distribution 
Distribution is the process of a medication 
transfer from the system circulation to utilization 
location. Amount of distribution of the medication 
determines its dispersion in the bodily fluids. In 
the course of the medication distribution, the 
most prominent are reactions of competitive 
inhibition of bonding to plasma proteints (Table 
1). Most antiepileptics are bonded in blood 
plasma to albumins and d – glyco protein (6). 
When the binding of AE is significant (over 90 
%), presence of another medication with greater 
affinity can immensly increase or decrease its 
plasma concentration, which is the reason why 
these interactions are of great importance. They 
can often be predicted and avoided owing to the 
knowledge of pharmacokinetic characteristics of a 
medication. For example, vigabatrin combined 
with phenitoin reduces its bonding to plasma 
proteins to 30 % and increases the free fraction 
of phenitoine (79). During the eduction of the 
medication with a reduced capability of bonding 
to plasma proteins from the medication–protein 
complex, its free fraction and clearance increase. 
Metabolism 
Clinically most significant interactions of AE 
occur during their metabolism. Most antiepileptic 
drugs are metabolized by utilization of CYP 2C9, 
CYP 2C19 and CYP 3A$ - the subtypes of hepatic 
enzyme cytochrome P 450 (7). Antiepileptic 
drugs are capable of inducing or inhibiting CYP 
liver enzyme, which lead to changes in their 
metabolic speed and their concentration in the 
blood. While combining antiepileptic therapy, it is 
important to know the influence of AE on the 
function of the liver enzymes. ( Table 2 ). Various 
combinations of antiepileptic drugs can be 
encountered clinically, often with carbamazepine, 
valproate or lamotrigine whereas the use of 
phenotoine and phenobarbitone is significantly 
reduced in modern therapy of epilepsy (6,8). 
 
Excretion 
Excretion presents the process of 
elimination of a medication from the human body 
where there are no clinically significant 
interactions of AE. Excretion can be influenced by 
medications that change renal clearance, renal 
circulation or urine ph, which lead to either 
slowing down or accelerating the process of 
elimination. It is well-known that urine is 
alcalised by Na – bicarbonate after the inebriation 
with barbiturates in order to eliminate the 
medication from the body. The concetration of 
lamotrigin is increased in the consecutive 
application of valproate whereas their mutual 
rivalry for the glucuronidation reaction reduces 
the clearance of lamotrigine. 
 
 
Table 1.Pharmacokinetics profiles AE drugs significant for interaction 
 
Antiepileptic 
Binding for plasma 
proteins (%) 
Metabolics 
transformation 
Renal elimination 
Halftime 
elimination(t½)(h) 
carbamazepine  75  yes no  16-24 
diazepam  98  yes no  24-48 
etosuximide  0  yes no  40-60 
phelbamate  25  yes yes  13-23 
lamotrigine  56  yes no  22-38 
phenobarbiton  50  yes yes  80-100 
vigabatrine  0  yes yes  5-7 
valproate  90  yes no  8-18 
levetiracetam  slabo  no yes  6-18 
clobazam  90  yes yes  18-42 
 
 
Table 2. Enzymes in metabolic reactions of antiepileptic drugs 
 
Antiepileptic  Influence of CYP enzymes and UDPGT   Important metabolism enzymes   
phenobarbiton induction  2C9,  3A4 
phenitoin induction  2C9,  3A4 
Carbamazepine induction  2C9,  3A4 
Levetiracetam  no influence   hidralases 
Valproac acid  inhibition  2C9 
Etosuximide  no influence   3A4 
lamotrigine  no influence   UDPGT 
 
٭ UDPGT-uridindiphosphoglukuronic transpherase 
 
 
 
 Acta Medica Medianae 2007,Vol.46                                 Clinically significant pharmacokinetic interactions... 
  57
Pharmacokinetic profile of the most 
important antiepileptics 
 
Phenitoine ( PHT ) 
 
The most important characteristic of the 
phenitoine metabolism is the activity of the 
enzymes CYP 2C9 and CYP 2C19 which take part 
in its oxidation. Consequently, the medication 
prepares for reaction after the conjunction of 
hydroxylation in para–position after which it is 
being eliminated from the body (7,8). Half – time 
for PHT elimination is 7 – 42 h. Phenitoine shows 
nonlinear kinetics due to which small changes in 
dosage can cause significant changes in 
medication concentration in the blood showing 
toxic effects. Phenitoine is a strong inductor of 
microsomal liver enzymes accelerating its own 
metabolism as well as the metabolism of other 
medications. The enzymes of importance for their 
biotransformation are CYP 2C9 and CYP 2C19  
 
Lamotrigine ( LTG ) 
Lamotrigine is rapidly and easily absorbed. 
It shows a high level of bio-access without 
significant metabolism of the first passage. After 
oral application, LTG reaches its maximum 
concentration in plasma in approximately 2,5 
hours. In the process of distribution,  55% of the 
medication is bonded to plasma proteins. 
Lamotrigine metabolism takes place in the liver 
via enzyme UDPGT (uridindiphtosphatglucuronic- 
transpherase) (8). After conjugation with 
glucuronic acid it is eliminated via urine, and only 
2% via feces. If the enzyme induction takes 
place, normal time for half-elimination that of 29 
h can be reduced to 14 h or increased to 70 h in 
combination with valproate (9). Generally 
speaking, time of the half- elimination is shorter 
in children (from 7 h to 80 h). Lamotrigine does 
not affect oxidative metabolic processes in the 
liver. However, the speed of its metabolism 
depends on the function of the liver enzymes 
(7,9). In the second metabolism phase, the 
variation in enzyme uridin glukonil – transferaze 
is noted, which conjugates with lamotrigine and 
prepares it for excretion. Patients with Gilbert's 
syndrome (genetic deficiency of bilirubine 
conjunction) show approximately 30% less clearance 
of lamotrigine, leading to its accumulation. 
 
Valproine acid (VPA) 
Valproine acid is resorbed rapidly and 
completely after oral application reaching its 
maximal concetration in 1-4 hours. Some disorders 
of the digestive tract and food  presence can 
postpone the beginning of its utilization. VPA is 
highly bonded to plasma proteins (about 90%), 
increasing the potential for interactions during 
the process of distribution. It almost completely 
undergoes the reactions of oxidation and 
glucuronidation, so that its unaltered form could 
remain unidentified in urine or feces (8,9). 
Metabolite derived from β – and ω – oxidation, 
2 propyl 2- pantenic acid and 2 – envalproine 
acid also show antiepileptic activity, while 2 – 
envalproine acid is accumulated in plasma and 
CNS in clinically significant concentrations. VPA 
is the inhibitor of microzomal liver enzymes. 
When combined with other antiepileptics both 
medications change their concentrations (10). 
The half – time of elimination, without the 
influence of other medications is 15 hours (5,7). 
 
Carbamazepine (CBZ) 
Carbamazepine shows limited affinity 
influencing its bio-access and a possibility of a 
greater influence of food and liquids present in 
the digestive tract. Maximal concentration of the 
medication in plasma is achieved in 4 – 8 hours 
after the oral application that can be prolonged to 
24 hours. The medicine is distributed equally 
troughout the whole body, so that the CNS 
concentrations could become equal to the plasma 
concentrations of drugs. CBZ bonds to plasma 
proteins about 75%. Metabolism takes place in 
the liver under the influence of oxidative 
enzymes forming 10,11 epoxide with the 
antiepileptic activity rapidly conjugated with 
glucuronic acid and eliminated from the body 
(6,7,8). CBZ is a potential inductor of microsomal 
liver enzymes. The time of half – elimination is 
10 – 20 hours. It is shortened in the presence of 
other antiepileptic drugs and inductors of liver 
enzymes (phenitoin, phenobarbitone). CBZ reduces 
plasma concentration of lamotrigine, oxcarbama-
zepame, topiramate, phelbamate (9,10). 
 
Phenobarbitone (PB) 
Absorbtion of PB is slow but complete as a 
result of the maximum concentration, 5 – 15 
hours after the oral application. The speed of 
absorption depends on pharmaco – technological 
form, quantity, types of food and liquid present in 
the digestive system. PB bonds to plasma protein 
up to 50% and slowly passing cheamato 
encephalic barrier. 25% of it is eliminated in the 
unaltered form allowing a forced diurese in the 
case of inebriation. The rest undergo 
hydroxylation in para–position thus getting 
inactive metabolite which is eliminated as free or 
as conjunct of glucuronic acid via urine. Half – 
time of elimination differs a lot between children 
and adults. In adults, the halftime of elimination 
is 96 – 100, while in children it is 30 – 70 hours (8). 
 
Levetiracetam 
Lev has been in use since 1999 and 
belongs to the latest generation of antiepileptic 
drugs. It is extremely an efficient and wide-
ranged AE, which does not require a therapeutic 
monitoring and is applied widely. Therapeutic 
concetration is 6 – 20 mg/l.LEV with a very 
favourable pharmacokinetic profile. Its features 
are a high-level bio-access and a weak bonding 
to plasma proteints (11). Its bio – transformation 
takes place in liver where inactive metabolites 
are produced by hydrolysis. Oxidative liver 
enzymes do not participate in metabolism of LEV 
which significantly reduces its potential for 
interactions. LEV is partially eliminated via 
kidneys unaltered. Its elimination half – time is 6 
– 8 h. In children, the elimination half – time is 
slightly shortened but prolonged in kidney diseases. 
The medication kinetics is linear, predictable with 
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(8,11). LEV does not show interactions with other 
AE medications. 
 
Gabapentin (GBP) 
Gabapentin represents a new generation of 
antiepileptics which has a characteristic dose– 
depending absorption. The process of absorption 
requires the presence of a carrier, which causes 
saturation kinetics and proves the necessity of 
therapeutic monitoring. GBP does not show 
significant influence on the level of the other 
antiepileptics, when applied in a combined 
therapy. Small interaction potential comes from 
its metabolism. 
 
Clobazame (CLB) 
Clobazame is an antiepileptic from the 
group of benzodiazepine which is mainly added 
as an adjuvant in therapy. After a rapid and 
complete resorbtion, maximum concentration of 
the medication in plasma is completed in 1-4 
hours. In plasma, it is highly bonded to plasma 
proteins (about 90%). Clobazame shows linear 
kinetics and substantial distribution. The 
metabolism is achieved via cytochromal enzymes 
CYP 3A4 and CYP 2C19, during which an active 
metabolite–norclobazame is produced (8). The 
elimination time of GLB is 18 hours while for 
norclobazame it is 42 hours. 
 
Interactions of AEs in a combined 
antiepileptic therapy 
 
In a combined antiepileptic therapy it is 
important to know the order of AEs application, 
because of their influence on liver enzymes and 
their affinity to bond to plasma proteins (1,5). 
Tables 3 and 4 show the influence of AE on each 
other. As the first medication, Carbamazepine, 
which is the inductor of liver enzymes, significantly 
decreases the level of valproate, while valproate 
added to carbamazepine does not significantly 
change its level, because the initiated enzyme 
inhibition is partially restored by induction. 
Clobazame, an adjuvant in antiepileptic therapy, 
especially in pediatric population, increases the 
level and effect of valproate and phenobarbitone at 
the same time reducing the level of carbamazepine. 
Clobazame has the unpredictable influence on 
phenitoine because of its nonlinear kinetics. The 
latest AEs generally show weaker influence on other 
antiepileptics, not significantly changing the 
concentration of the first AE (Table 4). That is the 
case with lamotrigine, the concentration of which 
directly depends on the influence of the first 
antiepileptic. Valproate, by its competitive inhibition 
in the second phase of metabolism, reduces 
excretion of lamotrigine due to which its level in 
plasma grows until the occurrence of undesireable 
effects, while carbamazepine significantly reduces 
the level of lamotrigine (12,13). Phenitoine 
produces interactions, e.g. with topamirate which 
has the affinity to bind to plasma proteins and 
increase free fraction of phenitoine (13). Zonisamide 
has not been studied enough up to now, but it is 
known that it changes the level of carbamazepine in 
an unpredictable way requiring therapeutic monito-
ring. Phelbamate significantly increases the level of 
valproate while reducing the level of carbamazepine, 
whereas it has the opposite effect on carbamaze-
pine metabolite, increasing its level and antiepileptic 
effect. Levetiracetame, which finds a widespread 
application in the contemporary therapy, shows an 
ideal kinetics and does not produce interactions with 
other AEs. Topamirate has clinically significant 
reduction effect on the level of valproate, because of 
its effect on liver enzymes (13). 
The influence of the second antiepileptic is 
quite larger if the therapy is begun with an 
antiepileptic of the latest generation (Table 5). By 
inducing valproate and phenitone, the level of 
lamotrigine is clinically significantly reduced. In 
contrast, carbamazepine and oxcarbamazepine 
increase its concentration (12). By adding another 
antiepileptic, zonisanide  and topamirate show a 
significant reduction in concentration. The inclusion 
of another antiepileptic has no significant clinical 
influence on vigabatrine (Table 5). The influence of 
other AEs on LEV has not been studied sufficiently, 
because it is rarely used as the first antiepileptic. 
 
Table 3. Change of the concentration of the first antiepileptic (AE I) after the absorption of the second (AE II) 
 
AEDI + 
AEDII 
PB PHT  PRM ESM CBZ DZP  CZP VPA  CLB 
PB AI  PHT↑↓  -  ESM↓↑ CBZ↓↓ DZP↓ CZP↓ VPA↓↓ 
CLB↓↓ 
NDMC↓↓ 
PHT  PB↑  AI 
PRM↑ 
PB↑ 
ESM↓↑ CBZ↓↓ DZP↓ CZP↓ VPA↓↓ 
CLB↓↓ 
NDMC↓↓ 
ESM  ↔  ↔  NA  ■  ↔  NA NA  VPA↓  NA 
CBZ  ↔  PHT↓↑ 
PRM↓ 
PB↑ 
ESM↓↓  AI  DZP↓ CZP↓ VPA↓↓ 
CLB↓↓ 
NDMC↑↑ 
VPA  PB↑↑ PHT↓↑ 
PRM↑↑ 
 
ESM↓↑ CBZ↓↓ DPZ↑↑  NA  ■  NA 
CLB  PB↑↑ PHT↓↑ 
PRM↑↑ 
 
NA  CBZ↓  NA NA  VPA↑  ■ 
٭CLB- clobazam, DZP- diazepam, NDMC- N-desmetilclobazam, CBZE – carbamazepam epoxid 
CZP- clonazepam, ETS- etosuximid, PRM- primidon, NA- announ, GBP- gabapentin, FBM- felbamat, LEV- 
levetiracetam, ZNS- zonisamid, OXC- oxcarbamazepam, 10OHOXC- 10,11 dihidroxycarbamazepam, AI- 
autoinduction 
↓plasma concentration decrease, ↓↓ significant plasma concentration decrease, ↑ plasma concentration increase, ↑↑ 
significant plasma concentration increase ↔ no change in plasma concentration, ?-unkown 
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Table 4. Influence of the new antiepileptic drugs on the concentration of the old AE 
AED I+ 
AED II 
PB PHT  PRM  ESM  CBZ  VPA 
VGT  ↔  PHT↓  ↔  NA  ↔  ↔ 
LTG  ↔  ↔  ↔  ↔  ↔  ↔ 
GBP  ↔  ↔  NA NA  ↔  ↔ 
TPM  ↔  PHT↑  ↔  NA  ↔  VPA↓ 
PGB  ↔  ↔  NA NA  ↔  ↔ 
FBM  PB↑↑ PHT↑↑  ? ?  CBZ↓ 
CBZE↑ 
VPA↑↑ 
TGB  ↔  ↔  ↔  NA  ↔  ↔ 
OXC  PB↑ PHT↑  ? ?  CBZ↓  ↔ 
LEV  ↔  ↔  ↔  NA  ↔  ↔ 
ZNS  ↔  PHT↑↑  ↔  NA  CBZ↑↓  ↔ 
 
Table 5. Influence of the old antiepileptic drugs on the concentration of the new AE 
 
AED I + 
AED II  VGB LTG GBP TPM PGB FBM  TGB  OXC  LEV ZNS 
PB  ↔  LTG↓↓  ↔  TPM↓↓  ↔  FBM↓↓ TGB↓↓ 10OHOXC↓  ↔  ZNS↓↓ 
PHT  ↔  LTG↓↓  ↔  TPM↓↓  ↔  FBM↓↓ TGB↓↓ 10OHOXC↓  ↔  ZNS↓↓ 
PRM  ↔  LTG↓↓  ↔  TPM↓↓  NA  FBM↓↓ TGB↓↓  ? NA  ZNS↓↓ 
ETS  NA NA NA  NA NA  ?  NA  NA  NA NA 
CBZ  ↔  LTG↑↑  ↔  TPM↓↓  ↔  FBM↓↓ TGB↓↓ 10OHOXC↓  NA  ZNS↓↓ 
VPA  ↔  LTG↓↓  ↔  TPM↓↓  ↔  ↔  ↔  ↔  ↔  ZNS↓↓ 
 
Table 6. Significant interactions of the antiepileptic drugs with other drugs 
 
First 
drug 
Second drug  Pharmacokinetic 
process 
Mechanism of interactions  Pharmacodynamics efect 
VPA antacide  apsorption  Adsorption     ↓bioaviability, VPA↓ 
AE  food  apsorption  binding  changeing of bioaviability 
VPA cholestiramin  distribution  binding VPA with 
cholestiramin  
VPA↓ 
PHT aspirin  metabolism  metabolism PHT↑ PHT↓ 
PHT fluconasol, 
ketoconasol 
metabolism  inhibition CYP 2C9, CYP 2C19  PHT↑ toxic ↑ 
PHT insuline  metabolism  inhibition  CYP  2C9  PHT ↑ 
PHT  doxicycline  metabolism  induction liver enzym   doxicyclin↓ 
 
PHT  fluoxetin  metabolism  inhibition CYP 2C9, CYP 2C19  PHT↑ 
CBZ Cimetidine  metabolism  metabolismCBZ↓   CBZ↑,adverse efect↑ 
CBZ doxicycline  metabolism  Induction CYP 3A4   Doxicyklin↓ 
CBZ Cortikosteroid 
drugs 
metabolism Induction  CYP 3A4  degrese efect 
corticosteroids 
CBZ  Macrolid antibiotics  metabolism  inhibition CYP 3A4 
metabolism CBZ↓ 
Toxic CBZ↑ 
LTG Antituberculotic 
drugs 
metabolism  metabolism LTG↑ LTG↓ 
VPA cimetidin  excretion  clirens VPA↓ VPA↑, toxic VPA↑ 
CBZ viloxazin  excretion  Inhibition of clirens CBZ  toxic efects CBZ↑ 
AE pesticide  metabolism Induction of liver enzym  pesticide ↓ 
 
Interactions of antiepileptics with 
other medications 
 
Because of the antiepileptic therapy specific 
features and the impossibility of its sudden 
discontinuance, practice has showed frequent 
interactions with medications, the metabolism of 
which is performed via the same enzymes, such as 
the case with antibiotics, oral contraceptives, 
hypoglycemics and antiarithmics. It is highly 
important to know about and prevent possible 
interactions, in order to minimize undesirable effects. 
The use of macrolidic antibiotics (clarytromi-
cine) and carbamazepine leads to clinically significant 
interaction, caused by slow metabolism, consequent 
accumulation and the occurence of toxic effects of 
carbamazepine (14,15). 
Chloramphenicol increases the plasma 
concentration of phenitoine because of the strong 
inhibition of liver enzymes, while riphampicine, 
the powerful inductor of microsomal liver enzymes, 
accelerates the metabolism of phenitoine and 
reduces its plasma concentration (14,16).  
Insulin activates interaction with phenitoine 
because of the inhibition of enzymes participating 
in its hydroxylation, primarily CYP 2C9, due to 
which the plasma concentration of phenitoine is 
increased. 
The outcome of a detailed research of 
pharmacokinetics has showed that valproate, 
lamotrigine, vigabatrine and gabapentine can be 
combined with contraceptives which contain only 
progesteron with levonorestrel based implants 
and medroxyprogesteron injections, without the 
risk of reduction of the contraceptive effect. Clinically significant pharmacokinetic interactions...                        Radmila Veličković-Radovanović et al. 
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In order to show improved clinically 
significant interactions of antiepileptics with other 
medications, their manifestation mechanism and 
pharmacodynamic effect are shown in Table 6 
(16,17,18). Vulnerable pediatric population, as 
well as patients with damaged liver and kidneys 
function, require special caution when combining 
antiepileptics. 
Generally speaking, medications with a 
shorter half–time elimination have a potential to 
perform interactions, due to which therapeutic 
monitoring is recommended. According to the 
literature-obtained data, the time needed for the 
maximum interaction effects varies in duration from 
3-4 days for valproate and carbamazepine, to 12 
days for exosuximide, 14 days for phenitoine and 
20 days for phenobarbitone. The data is of special 
significance to epileptologists (7,16). 
Populational pharmacokinetic analysis is very 
significant in studying interactions of antiepileptics 
both with each other and with other medications. 
Based on the insufficient data about the plasma 
concentrations of antiepileptics and taking into 
consideration patients from specific population, 
the analysis can verify the correlation between 
medications, their interrelated influence and 
correction in the therapy applied. 
This information is relevant for the pediatric 
population, since they require special caution in 
the AEs dosage titration. Relevant factors taken 
into account are: sex, age habits, body weight 
and medications (3). Populational analysis 
confirms the necessity of the AE therapeutic 
monitoring. With this sort of analysis it is possible 
to confirm the life style effect e.g. smoking, for 
instance, reduces the effect of antiepileptic 
therapy. Using the same analytical method, the 
influence of new antiepileptics has been tested on 
the reducition of the contraceptives efficiency. 
Children and the elderly with chronical 
diseases require special attention because they 
have a different therapeutic response to AEs 
which is the consequence of interactions of 
antiepileptics with other medications. 
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Antiepileptici (AE) pokazuju klinički značajne interakcije medjusobno i sa drugim lekovima zbog 
specifičnog farmakokinetičkog profila i relativno male terapijske širine. Klinički najznačajnije interakcije 
AE se dešavaju tokom njihovog metabolizma i distribucije. U kombinovanoj antiepileptičkoj terapiji od 
važnosti je poznavanje redosleda primene AE zbog njihovog uticaja na enzime jetre i afiniteta 
vezivanja za proteine plazme. Veći poten-cijal interakcije imaju AE sa kraćim poluvremenom 
eliminacije, zbog čega se preporučuje njihov terapijski monitoring. Populaciona farmakokinetička 
analiza može pružiti značajne podatke vezane za interakcije AE sa drugim lekovima. Poseban rizik za 
nastanak interakcija ima vulnerabilna, pedijatrijska populacija i bolesnici sa oštećenjem funkcije jetre i 
bubrega. Acta Medica Medianae 2007;46(4):55-60. 
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